Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.41 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13936447 | 1.00 | GLP1R (0.55) | GLP1RMEN1KMT2AGAATDP1 | |
| SCHEMBL13936449 | 1.00 | GLP1R (0.55) | GLP1RMEN1KMT2AGAATDP1 | |
| SCHEMBL13936445 | 1.00 | GLP1R (0.55) | GLP1RMEN1KMT2AGAATDP1 | |
| SCHEMBL3485751 | 0.90 | GLP1R (0.45) | GLP1RMEN1KMT2AGAATDP1 | |
| SCHEMBL3485748 | 0.90 | GLP1R (0.45) | GLP1RMEN1KMT2AGAATDP1 | |
| SCHEMBL20797923 | 0.90 | MEN1 (0.50) | GLP1RMEN1KMT2AGAATDP1 | |
| SCHEMBL20797924 | 0.90 | MEN1 (0.50) | GLP1RMEN1KMT2AGAATDP1 | |
| SCHEMBL13936448 | 0.89 | GLP1R (0.54) | GLP1RMEN1KMT2AGAATDP1 | |
| SCHEMBL13936450 | 0.89 | GLP1R (0.54) | GLP1RMEN1KMT2AGAATDP1 | |
| SCHEMBL13699549 | 0.87 | GLP1R (0.56) | GLP1RMEN1KMT2AGAATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036353-A1 | Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers | NOVO NORDISK A/S (DK) | 2009-02-05 | — | — | US | disclosed |
| US-20090036353-A1 | Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers | NOVO NORDISK A/S (DK) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036353-A1 | Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers | INSR, IAPP, IGF1R | GLP1R 14/4885MEN1 278/4885KMT2A 4457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.